<DOC>
	<DOCNO>NCT00940758</DOCNO>
	<brief_summary>The purpose study evaluate dose-limiting toxicity ( DLT ) , toxicity profile , maximum tolerate dose ( MTD ) characterize pharmacokinetics biweekly PEP02 treatment .</brief_summary>
	<brief_title>Phase I Pharmacokinetic Study Biweekly PEP02 mCRC Refractory 1st-line Oxaliplatin Base Therapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histopathologically confirm metastatic colorectal cancer Documented disease progression firstline chemotherapy contain oxaliplatin Both gender , age 18 year ECOG performance status 0 1 Adequate organ marrow function Written inform consent participate study Have receive irinotecan treatment With active CNS metastasis ( indicated clinical symptom , cerebral edema , steroid requirement , progressive growth ) With clinically significant gastrointestinal disorder ( e.g . bleeding , inflammation , obstruction , include partial complete obstruction secondary peritoneal carcinomatosis , diarrhea &gt; grade 1 ) With uncontrolled intercurrent illness could limit study compliance consider ineligible study investigator include , NOT limit , follow : ongoing active infection require antibiotic treatment , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia psychiatric illness social situation would preclude study compliance With primary malignancy , except remain diseasefree 3 year curative treatment . Prior chemotherapy within 3 week Major surgery radiotherapy within 4 week Prior participation investigational drug study within 3 week History allergic reaction liposome product Pregnant breastfeeding ( urine pregnancy test must perform patient childbearing potential entering study , result must negative )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>